Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.

PMID:
19129749
2.

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M.

Clin Pharmacol Ther. 2009 May;85(5):520-6. doi: 10.1038/clpt.2008.251. Epub 2009 Jan 7.

PMID:
19129748
3.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

List JF, Woo V, Morales E, Tang W, Fiedorek FT.

Diabetes Care. 2009 Apr;32(4):650-7. doi: 10.2337/dc08-1863. Epub 2008 Dec 29.

4.

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association.; European Association for Study of Diabetes..

Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.

5.

10-year follow-up of intensive glucose control in type 2 diabetes.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.

N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.

6.

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. doi: 10.1124/jpet.108.140210. Epub 2008 Jun 26.

7.

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM.

Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20.

8.

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group..

N Engl J Med. 2007 Oct 25;357(17):1716-30. Epub 2007 Sep 21.

9.

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M.

J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.

10.

Thiazolidinediones, insulin resistance and obesity: Finding a balance.

Wilding J.

Int J Clin Pract. 2006 Oct;60(10):1272-80. Review.

PMID:
16981971
11.

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO.

Diabetes Care. 2004 Jan;27(1):17-20.

PMID:
14693960
12.

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.

Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H.

Diabetes Care. 2003 Dec;26(12):3273-9.

PMID:
14633813
13.

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group..

Diabetes Care. 2002 Feb;25(2):330-6. Erratum in: Diabetes Care 2002 Jul;25(7):1268.

PMID:
11815505
14.

Combination therapies with insulin in type 2 diabetes.

Yki-Järvinen H.

Diabetes Care. 2001 Apr;24(4):758-67. Review. No abstract available.

PMID:
11315844
15.

T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.

Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, Yano H, Seino Y, Tsuda K.

Metabolism. 2000 Aug;49(8):990-5.

PMID:
10954015
16.

Glucose transporters: structure, function and consequences of deficiency.

Brown GK.

J Inherit Metab Dis. 2000 May;23(3):237-46. Review.

PMID:
10863940
17.

Combining insulin and oral agents.

Buse J.

Am J Med. 2000 Apr 17;108 Suppl 6a:23S-32S. Review.

PMID:
10764847
19.

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

Mäkimattila S, Nikkilä K, Yki-Järvinen H.

Diabetologia. 1999 Apr;42(4):406-12.

PMID:
10230643
20.

Supplemental Content

Support Center